The investigational non-steroidal MRA balcinrenone in cardiorenal medicine: current evidence and future perspectives
For almost 2 decades, renin-angiotensin-system (RAS)-blockade was the basic pillar of therapy for cardiorenal protection in patients with chronic kidney disease (CKD) and albuminuria. Novel therapies, such as sodium-glucose co-transporter type 2 inhibitors (SGLT2is) and the non-steroidal mineralocorticoid-receptor-an...